EVOKE PHARMA, INC. Item 8.01 Other Events
On
In addition, no future ANDA filer will be eligible to receive 180-day generic exclusivity for an ANDA that references GIMOTI®. This regulatory pathway is typically highly sought after by generic firms.
Safe Harbor Statement
Evoke cautions you that statements included in this report that are not a
description of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend," "target,"
"project," "contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negatives of these terms or other similar expressions. These
statements are based on the company's current beliefs and expectations. These
forward-looking statements include statements regarding: the anticipated scope
and term of any patent protection for GIMOTI; and Evoke's belief in the strength
of the GIMOTI patent protection and ability to defend its intellectual property
rights. The inclusion of forward-looking statements should not be regarded as a
representation by Evoke that any of its plans will be achieved. Actual results
may differ from those set forth in this press release due to the risks and
uncertainties inherent in Evoke's business, including, without limitation:
Evoke's ability to obtain, maintain and successfully enforce intellectual
property protection for GIMOTI; Evoke's ability to obtain additional financing
as needed to support its operations; Evoke is entirely dependent on the success
of GIMOTI; and other risks and uncertainties detailed in Evoke's prior press
releases and in the periodic reports it files with the
--------------------------------------------------------------------------------
© Edgar Online, source
